In insulin-resistant patients, ABA supplementation could contribute to the reduction in post-prandial hyperglycemia, in conjunction with oral hypoglycemic drugs, by synergizing with the action of endogenous insulin, via a different signaling pathway, eliciting an increased muscle glucose uptake. Here, INS is linked to Hyperglycemia.